Immune Design Corp  

(Public, NASDAQ:IMDZ)   Watch this stock  
Find more results for Susan M. Coleman
7.30
+0.04 (0.55%)
After Hours: 7.30 0.00 (0.00%)
Jul 26, 5:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.10 - 7.53
52 week 6.43 - 23.59
Open 7.23
Vol / Avg. 65,437.00/138,725.00
Mkt cap 149.17M
P/E     -
Div/yield     -
EPS -2.12
Shares 20.15M
Beta     -
Inst. own 98%
Aug 10, 2016
Q2 2016 Immune Design Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 8, 2016
Immune Design Corp at Jefferies Healthcare Conference
May 24, 2016
Immune Design Corp at UBS Global Healthcare Conference
May 10, 2016
Q1 2016 Immune Design Corp Earnings Call
May 10, 2016
Q1 2016 Immune Design Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -659.90% -414.77%
Operating margin -678.64% -415.19%
EBITD margin - -412.64%
Return on average assets -44.58% -40.55%
Return on average equity -47.40% -44.99%
Employees 41 -
CDP Score - -

Address

1616 Eastlake Ave E Ste 310
SEATTLE, WA 98102-3788
United States - Map
+1-206-6820645 (Phone)
+1-206-6820648 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).

Officers and directors

Edward E. Penhoet Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Carlos V Paya President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Stephen R. Brady J.D. Principal Financial Officer, Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Jan Henrik Ter Meule M.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Christopher Whitmore Vice President - Finance and Administration
Bio & Compensation  - Reuters
Adam R. Craig M.D. Ph.D. Interim Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Wayne R. Gombotz Ph.D. Chief Development Officer
Age: 55
Bio & Compensation  - Reuters
Susan L. Kelley M.D. Director
Age: 61
Bio & Compensation  - Reuters
David Baltimore Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 65
Bio & Compensation  - Reuters